Related Experiment Video
Updated: Feb 14, 2026

Ultrafast Lignin Extraction from Unusual Mediterranean Lignocellulosic Residues
Published on: March 9, 2021
Eyelashes Trichomegaly: An Unusual Side Effect of Gefitinib Therapy
Chaturbhuj R Agrawal1, Pankaj Goyal1, Dinesh Chandra Doval1
1Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Abstract:
Evolution of targeted therapy has changed the spectrum of treatment in oncology since the past two decades as lots of newer agents are being added to the pharmacologic armamentarium of cancer therapy. Epidermal growth factor receptor inhibitors form one such advancing field with many newer agents being investigated and they are used in wide variety of malignancies such as head and neck cancer, lung cancer, and even gastrointestinal malignancies such as pancreatic cancer. Various troublesome side effects of these agents include diarrhea, severe fatigability, severe skin rashes, and deranged liver function tests which may require treatment interruption or dose reduction resulting in decreased response to treatment. However, some of the side effects may not require dose modification but incidentally observed and does not impact patient's quality of life. One such effect is trichomegaly which is very rarely observed with such agents. Herein, this conversation we report a 52-year-old female case of metastatic carcinoma lung who developed trichomegaly of eyelashes while on gefitinib therapy.
Insights
Epidermal growth factor receptor inhibitors, like gefitinib, are advancing cancer therapy but can cause side effects. This case highlights trichomegaly, or eyelash growth, as a rare, incidental side effect in lung cancer patients.
Area of Science:
- Oncology
- Pharmacology
- Dermatology
Background:
- Targeted therapies, particularly epidermal growth factor receptor (EGFR) inhibitors, have significantly advanced cancer treatment over the past two decades.
- These agents are utilized across various malignancies, including lung, head and neck, and gastrointestinal cancers.
Observation:
- Common side effects of EGFR inhibitors include diarrhea, fatigue, skin rashes, and liver function abnormalities, often necessitating treatment adjustments.
- Trichomegaly, characterized by abnormal eyelash growth, is a rare and often incidentally observed side effect associated with these therapies.
- This report details a case of trichomegaly in a patient undergoing treatment for metastatic lung carcinoma.
Findings:
- A 52-year-old female patient with metastatic lung carcinoma developed significant eyelash growth (trichomegaly) during gefitinib therapy.
- The observed trichomegaly did not necessitate dose modification or interruption of gefitinib treatment.
- This finding suggests trichomegaly can be an incidental, non-debilitating side effect of EGFR inhibitor therapy.
Implications:
- The occurrence of trichomegaly highlights the diverse and sometimes unexpected side effect profile of targeted cancer therapies.
- Recognizing rare side effects like trichomegaly is crucial for comprehensive patient monitoring and management in oncology.
- Further investigation may elucidate the precise mechanisms underlying EGFR inhibitor-induced trichomegaly and its clinical significance.
Related Concept Videos
Unusual Results
According to the range rule of thumb, any value above or below two standard deviations, 2σ from the mean, μ is considered unusual.
Maximum unusual value =...
z Scores and Unusual Values
This score indicates how far a value is from the mean in terms of standard deviation. For example, if a data value has a z score of +1, the researcher can infer that the particular data value is one standard deviation above the mean. If another data...
Gene Therapy
Group Therapy
Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
Drug Therapy
Antianxiety Medications

